Personalised medicine is envisioned to greatly impact disease management in chronic inflammatory diseases, such as Rheumatoid Arthritis (RA) and multiple sclerosis (MS). Preselect Diagnostics tackles the well-recognised but unmet need expressed by rheumatologists and neurologists for biomarkers to diagnose the very early stage, progression, and response to therapy.
Current treatments with biologicals, such as tumour necrosis factor (TNF)-blockers and B-cell depleting agents in RA, and interferon-β in MS are very costly, may cause serious side effect and are not effective in all patients.
Preselect Diagnostics has generated an intellectual property position that will form the basis for the development of tests to diagnose preclinical RA in asymptomatic individuals, and predict response to treatment with interferon-β in MS, and TNF blockers and B-cell depleting agents in RA. In the long- term, the company aims to generate a good return by outlicense their tests to prospective companies after proof of concept has been reached.
Preselect’s longer-term goal is to broaden the scope of indications for their tests. Moreover, their expertise will be used to generate predictive tests for other biologicals.